

POWERING speeding up INNOVATION progress


LANDMARKS 2018

EMBODYING THE GREAT AMBITION TO CURE CANCER

Gustave Roussy is the leading Cancer Centre in Europe and one of the ten most prominent comprehensive cancer centres in the world. It treats patients of all ages with every type of cancer and is expert in the treatment of rare and complex tumours.

By embracing the values of originality, respect for the person, inventiveness and sharing, the staff at Gustave Roussy take up the ongoing challenge to treat patients with the most advanced methods.

Our mission is vital: to go beyond scientific frontiers, always re-examine the treatments we offer and explore every avenue of innovation. Our doctors and researchers devote their energy and skills to this great challenge: to be an engine of progress, to extend knowledge and to offer patients the most appropriate care, while nourishing the hope of curing cancer in the 21st century.



ADVENTUROUS RESEARCH

Gustave Roussy, as a driver of progress, brings together the best researchers in fundamental, clinical and translational research who maintain strong links with Paris-Sud University, Inserm, the CNRS and CentraleSupélec. Very close collaboration between research workers and doctors at the Institute means that we can offer our patients access to the latest therapeutic advances within the shortest time-scale.

The effectiveness of the Gustave Roussy model of an integrated centre for research and clinical practice is reflected in the impact of its scientific publications and the prominence of its researchers at international conferences. The Institute's research teams are devoted principally to three research priorities: precision medicine, immunotherapy and DNA repair. New avenues are being explored, with artificial intelligence in the first rank.



3,900

patients have participated in the Gustave Roussy Precision Medicine programme since 2011

435

patients included in early trials

10

molecular medicine trials sponsored by Gustave Roussy

- o **Immunotherapy** 
37 phase I trials; 25 phase I-II trials; 46 phase II trials and 34 phase III trials
- o

84

patent families in the portfolio



1,168

patients recruited to MOSCATO-01

581

patients treated with immunotherapy in clinical trials in 2017

100

doctoral research students (PhD)



556

patients recruited to MOSCATO-02 (at April 2018)

CARING AND INNOVATIVE TREATMENT

Gustave Roussy declares its commitment to being a motor of progress in oncology in terms both of therapy and of care pathways. With innovative treatment which is the least invasive possible and is delivered under the safest conditions, the Institute offers its cancer patients high quality care from diagnosis to treatment.

Patients at Gustave Roussy, a University Hospital, have access to a complete therapeutic arsenal: Immunotherapy, Chemotherapy, Radiotherapy, Surgery, Interventional Radiology, DNA sequencing, Reparative Surgery and Robotic Surgery.

As a result of the successful marrying of research and clinical care, advances made in research are translated with little delay into clinical trials and then into treatment offered to the greatest number. The Drug Development Department (DITEP) carries out phase I, I/II and II trials with complex logistics that allow patient access to novel therapies.

250,300

medical outpatient visits

125,500

hospital stays, 84% of which are in ambulatory care

14,560

patients admitted to hospital, of which 9,220 in ambulatory care

6,000

patients treated with chemotherapy



2,550

patients treated by interventional radiology



5,800

emergency consultations



3,900

patients treated by radiotherapy

650

patients treated with high precision radiosurgery

4 400

patients treated by surgery

SHARING OUR KNOWLEDGE

Gustave Roussy is committed to teaching and transmission of its expertise in the oncology-based training of doctors, researchers, nurses, students and others involved in the care of cancer patients. These high quality teaching programmes are delivered by recognised experts and contributors to advances in oncology, and facilitate the rapid spread of knowledge of new treatments and the ongoing development of skills.

The École des Sciences du Cancer was established by Gustave Roussy and the Paris-Sud University in 2012 and is unique in France. Students are trained by a top-grade teaching body for the new career posts in oncology through courses leading to degrees and other qualifications.

The School has developed a modern teaching model based on visual aids, information technology and participatory learning. A complete digital teaching facility has been added to the educational resources. In addition, the École Doctorale de Cancérologie (Doctoral Oncology School) is the only doctoral programme in France restricted to oncology. Its annual intake of 55 new doctoral students can choose between 85 Research Units.

3,000

students and staff trained each year

240

specialist doctors involved in teaching



23

university teachers

40

scientific seminars and master classes

59,000

hours of training, 6,000 being at university level

2,000

videos on line

7,000

individuals registered on the digital teaching facility

2

mobile phone apps: a practical Oncology manual for all medical practitioners and Oncology module UE9 for medical students



280

articles published in journals with an impact factor above 10 (other than conference publications)

CHALLENGES MET TOGETHER

A “private establishment of collective benefit”, the Institute, just like the Gustave Roussy Research Foundation, has approval to receive donations and bequests. The generosity of the public is an essential component of support for our research and care teams. It is a real driver of progress. It gives Gustave Roussy staff the means to make further advances in the fight against cancer; in fundamental, clinical and translational research; and in improving patients’ quality of life.

In 2017, Gustave Roussy launched two major fund-raising campaigns: “Curing Cancer in the 21st Century” and “Curing Childhood Cancer in the 21st Century” aiming to collect 50 million and 10 million euros respectively by 2020.

In 2017, 34 M€ donated to the Institute and the Gustave Roussy Foundation financed major projects: acquisition of latest generation equipment, renovation of departments, establishment of research teams and innovative programmes dedicated to research and to patient care.

Financial transparency, good management of donations and respect for the wishes of donors are constants at Gustave Roussy, which, since 2009, has held the Charter Committee’s “Donate in confidence” accreditation.

€34M

in donations and bequests to Gustave Roussy and its Foundation



€8,5M

raised through bequests and gifts

+65%

increase in giving compared with 2016

90,000

donations, 25,968 being from new sources

€56,000

collected through SMS

€6M

devoted to installing the most modern radiotherapy equipment

€1.5M

contributing to the creation of a new interventional radiology theatre



€700,000

to purchase a CyTOF (flow cytometry machine)

GUSTAVE ROUSSY IN FIGURES

48,600

patients seen in outpatients
of whom 11,400 were attending
their first appointment



34

research teams
in 10 Units

414

in-patient beds

104

Day Hospital places

3,100

employees,
including 1,200 nursing staff
and 515 doctors



€375.6M

overall budget

62

articles published in journals
with an impact factor
between 20 and 30
(excluding conferences)

3,617

patients included
in clinical research studies
representing

28 %

of patients treated in 2017



26

University diplomas
and one Master's
degree in Oncology



3 000

students and professionals
trained per year



428

clinical trials in 2017,
of which


64

sponsored by Gustave Roussy

BEST EFFORTS IN THE SERVICE OF MEDICAL EXCELLENCE

Driven forwards by Gustave Roussy's values of creativity, dynamism, empathy and collaboration, the Institute's research teams, teachers, doctors and nurses put innovation at the heart of all of their activities.

“*We tackle our mission with optimism and pragmatism: accelerating progress.*”



Professor Alexander Eggermont,
General Director



www.gustaveroussy.fr/en

114, rue Édouard-Vaillant
94805 Villejuif Cedex - France

**GUSTAVE
ROUSSY**
CANCER CAMPUS
GRAND PARIS

